多黏菌素B治疗碳青霉烯类耐药革兰阴性菌感染者全因死亡影响因素的Meta分析
x

请在关注微信后,向客服人员索取文件

篇名: 多黏菌素B治疗碳青霉烯类耐药革兰阴性菌感染者全因死亡影响因素的Meta分析
TITLE: Meta-analysis of influential factors for all-cause mortality in patients with carbapenem-resistant Gram-negative bacteria treated with polymyxin B
摘要: 目的 系统评价多黏菌素B治疗碳青霉烯类耐药革兰阴性菌(CR-GNB)感染者全因死亡的影响因素。方法检索PubMed、Embase、TheCochraneLibrary、WebofScience、万方、维普、中国生物医学文献数据库和中国知网,收集多黏菌素B治疗CR-GNB感染者30d内或28d内全因死亡的临床报道,检索期限为数据库建库至2025年7月。筛选文献、提取数据、评价文献质量后,采用RevMan5.4软件进行Meta分析。结果共纳入12篇文献,涉及1326例患者,其中死亡患者为529例,死亡率为39.89%。Meta分析结果显示,合并心血管疾病[OR=2.06,95%CI(1.37,3.09),P=0.005]、序贯器官衰竭评估(SOFA)评分升高[OR=1.20,95%CI(1.07,1.35),P=0.003]、机械通气[OR=2.35,95%CI(1.65,3.34),P<0.001]、连续性肾脏替代治疗(CRRT)[OR=2.58,95%CI(1.67,3.97),P<0.001]、血流感染[OR=3.24,95%CI(2.19,4.78),P<0.001]、多部位感染[OR=1.51,95%CI(1.03,2.20),P=0.03]、感染性休克[OR=3.19,95%CI(1.94,5.24),P<0.001]、使用血管活性药物[OR=2.90,95%CI(1.97,4.27),P<0.001]、发生急性肾损伤(AKI)[OR=2.17,95%CI(1.41,3.36),P<0.001]是多黏菌素B治疗CR-GNB感染者全因死亡的危险因素,多黏菌素B用药疗程延长[OR=0.92,95%CI(0.86,0.99),P=0.03]和CR-GNB感染后早期用药[OR=0.47,95%CI(0.25,0.85),P=0.01]是保护因素。结论合并心血管疾病,接受机械通气或CRRT,发生血流感染、多部位感染、感染性休克,合并使用血管活性药物,出现AKI且SOFA评分升高的CR-GNB感染者,全因死亡风险较高;而延长多黏菌素B用药疗程(>7d)、在确诊CR-GNB感染后48h内早期给药,可显著降低该类患者的全因死亡风险。
ABSTRACT: OBJECTIVE To systematically evaluate the influential factors for all-cause mortality in patients with carbapenem-resistant Gram-negative bacteria (CR-GNB) treated with polymyxin B. METHODS PubMed, Embase, the Cochrane Library, Web of Science, Wanfang Data, VIP, CBM and CNKI were searched to collect clinical studies on all-cause death within 30 days or 28 days after treatment with polymyxin B in patients with CR-GNB infection from database establishment to July 2025. After literature screening, data extraction and evaluation of literature quality, meta-analysis was performed using RevMan 5.4 software. RESULTS A total of 12 studies were included, involving 1 326 patients, among whom 529 patients died, with a mortality rate of 39.89%. Meta-analysis results showed that combined with cardiovascular disease [OR=2.06, 95%CI (1.37, 3.09), P =0.005 ] , increased Sequential Organ Failure Assessment (SOFA) score [OR=1.20, 95%CI (1.07, 1.35), P =0.003 ] , mechanical ventilation [OR=2.35, 95%CI (1.65, 3.34), P <0.001 ] , continuous renal replacement therapy (CRRT) [OR=2.58, 95%CI (1.67, 3.97), P <0.001 ] , bloodstream infection [OR=3.24, 95%CI (2.19, 4.78), P <0.001 ] , multiple-site infection [OR=1.51, 95%CI (1.03, 2.20), P =0.03 ] , septic shock [OR=3.19, 95%CI (1.94, 5.24), P <0.001 ] , use of vasoactive drugs [OR=2.90, 95%CI (1.97, 4.27), P <0.001 ] , and the occurrence of acute kidney injury (AKI) [OR=2.17, 95%CI (1.41, 3.36), P <0.001 ] were risk factors for all-cause mortality in patients with CR-GNB infection treated with polymyxin B. Conversely, an extended duration of polymy xin B treatment [OR=0.92, 95%CI (0.86, 0.99), P =0.03 ] and early administration after CR-GNB infection [OR=0.47, 95%CI (0.25, 0.85), P =0.01 ] were protective factors. CONCLUSIONS Patients with cardiovascular disease, receiving mechanical ventilation or CRRT, having bloodstream infection, multiple-site infection or septic shock, combining with vasoactive drugs, with AKI and increased SOFA scores have a higher risk of all-cause mortality. Conversely, extending the duration of polymyxin B treatment (beyond 7 days) and early administration within 48 hours after confirmed CR-GNB infection can significantly reduce the risk of all-cause mortality.
期刊: 2026年第37卷第07期
作者: 谭瑞娟;王立丹;杜梅;马红芳;张晓燕
AUTHORS: TAN Ruijuan,WANG Lidan,DU Mei,MA Hongfang,ZHANG Xiaoyan
关键字: 多黏菌素B;碳青霉烯类耐药革兰阴性菌;全因死亡;影响因素;Meta分析
KEYWORDS: polymyxin B; carbapenem-resistant Gram-
阅读数: 25 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!